Outdated System Preventing Breast Cancer Patients Getting Access To Early Treatment In England, Says Roche

Roche Pharma AG has been scorned once again by the England's health technology appraisal body NICE – with the pricing group this time rejecting the big pharma's breast cancer treatment Perjeta (pertuzumab) for regular use on the NHS as a neoadjuvant therapy.

In a May 20 draft guidance, NICE (the National Institute for Health and Care Excellence) said it was not recommending Perjeta, in combination with Herceptin (trastuzumab) and chemotherapy, as a neoadjuvant (pre-surgery) treatment on the NHS for human epidermal growth factor receptor 2 (HER2)-positive breast cancer. The committee stated a number of reasons for its decision, including an unsubstantial data package from Roche; concerns around the use of pathological complete response as a substitute for overall survival outcomes; and the treatment not being a cost-effective use of funds.

NICE also had issues with Roche's pricing models for Perjeta in this indication, which used England's Cancer Drugs Fund as...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip